Zenotech has two heads and gets behind as Daiichi Sankyo watches on
This article was originally published in Scrip
All is not settled at the Indian biotech firm, Zenotech Laboratories, with its founder complaining that two heads are not better than one, and lamenting that Daiichi Sankyo, now in effect a majority shareholder in the company, has not been sufficiently involved in running it. Industry analysts are now becoming concerned that intra-management carping at Zenotech is causing the company to lose ground on its rivals.
You may also be interested in...
Gland Pharma, controlled by Chinese group Fosun, makes shining debut on Indian stock markets despite a lukewarm response to its IPO. Will the buoyant market sentiment sustain amid edgy India-China relations?
A senior executive of Janssen’s supply chain leadership team outlines how the company handled activities in Asia Pacific at the height of the coronavirus outbreak, including ensuring continuous and rapid supplies of critical medicines in China. The company is also prepping against “multiple scenarios” to ensure global access for its potential COVID-19 vaccine.
Expert outlines how pharma can create resilient and secure supply chains and some benefits of localization.